LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE)

Journal of Clinical Epidemiology

Volumn 62, Issue 3, 2009, Pages 328-336

  Johnson, Kent R ^a   Freemantle, Nick ^b   Anthony, Danielle M ^a   Lassere, Marissa N D ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biomarker; Forecasting; LDL cholesterol; Levels of evidence; Statins; Surrogate

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL STUDY; CLINICAL TRIAL; FORECASTING; HUMAN; MORTALITY; MULTIPLE REGRESSION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURROGATE THRESHOLD EFFECT; SURVIVAL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLACEBOS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 58849099511     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2008.06.004     Document Type: Article

References (72)

1. Fleming T.R., and DeMets D.L. Surrogate endpoints in clinical trials: Are we being misled?. Ann Int Med 125 (1996) 605-613
2. De Gruttola V., Fleming T., Lin D.Y., and Coombs R. Perspective: validating surrogate markers-are we being naive?. J Infect Dis 175 2 (1997) 237-246
3. Temple R.J. Clinical measurement in Drug Evaluation. Nimmo WS, Tucker GT. A regulatory authority's opinion about surrogate endpoints (1995), John Wiley & Sons Ltd 3-22
4. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 4 (1989) 431-440
5. Freedman L.S., Graubard B.I., and Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11 2 (1992) 167-178
6. Daniels M.J., and Hughes M.D. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16 17 (1997) 1965-1982
7. Burzykowski T., Molenberghs G., and Buyse M. The evaluation of surrogate endpoints (2005), Springer, New York
8. Lassere M.N., Johnson K.R., Boers M., Tugwell P., Brooks P., Simon L., et al. Definitions and Validation Criteria for Biomarkers and Surrogate Endpoints: Development and Testing of a Quantitative Hierarchical Levels of Evidence Schema. J Rheumatol 34 (2007) 607-615
9. Weir C.J., and Walley R.J. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 25 2 (2006) 183-203
10. Lassere M.N., Johnson K.R., Hughes M., Altman D., Buyse M., Galbriath S., et al. Simulation studies of surrogate endpoint validation using single trial and multi-trial statistical approaches. J Rheumatol 34 (2007) 616-619
11. Burzykowski T., and Buyse M. An alternative measure for meta-analytic surrogate endpoint validation. Burzykowski T, Molenberghs G, Buyse M. The evaluation of surrogate endpoints (2005), Springer, New York 323-40
12. Sargent D, Wieand S, Benedetti J, Labianca D, Haller L, Shepherd L, et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Associated Presentation at American Society of Clinical Oncology 2004 Annual Meeting. Accessed 15 January 2006; http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-009587,00.asp.
13. Johnson K.R., Ringland C., Stokes B.J., Anthony D., Freemantle N., Alar I., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncology 7 9 (2006) 741-746
14. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s). Lancet 344 8934 (1994) 1383-1389
15. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (lipid) study group. N Engl J Med 339 19 (1998) 1349-1357
16. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
17. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the miracl study: a randomized controlled trial. JAMA 285 13 (2001) 1711-1718
18. Thompson P.L., Meredith I., Amerena J., Campbell T., Sloman J.G., Harris P., et al. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the pravastatin in acute coronary treatment (PACT) trial. Am Heart J 148 1 (2004) e2-e8
19. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., et al. for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 24 (2002) 3215-3222
20. Anderson K., Wilson P., Odell P., and Kannel W. An updated coronary risk profile: A statement for health professionals. Circulation 83 (1991) 356-362
21. Tobin J. Estimation of relationships for limited dependent variables. Econometrics 26 (1958) 24-36
22. Royston P., and Altman D.G. Regression using fractional polynomials of continuous covariates: Parsimonious parametric modelling. Applied Statistics 43 (1994) 429-467
23. Altman D.G. Practical Statistics for Medical Research (1991), Chapman and Hall, London
24. StatCorp. Stata Statistical Software: Release 9. College Stattion, TX: StataCorp LP (2005)
25. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288 23 (2002) 2998-3007
26. Athyros V.G., Papageorgiou A.A., Mercouris B.R., Athyrou V., Symeonidis A., Basayannis E., et al. Treatment with atorvastatin to the national cholesterol educational program goal versus 'usual' care in secondary coronary heart disease prevention. The greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Current Medical Research & Opinion 18 4 (2002) 220-228
27. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D., Beere P., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of afcaps/texcaps. Air force/texas coronary atherosclerosis prevention study. JAMA 279 20 (1998) 1615-1622
28. Shepherd J., Cobbe S.M., Ford I., Isles C., Lorimer A.R., Macfarlane P., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333 20 (1995) 1301-1307
29. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J., Rutherford J., Cole T., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335 14 (1996) 1001-1009
30. Shepherd J., Blauw G.J., Murphy M.B., Bollen E., Buckley B., Cobbe S., et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Prosper study group. Prospective study of pravastatin in the elderly at risk. Am J Cardiol 84 10 (1999) 1192-1197
31. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 9364 (2003) 1149-1158
32. Furberg C.D., Pitt B., Byington R.P., Park J.S., and McGovern M.E. Reduction in coronary events during treatment with pravastatin. Plac i and plac ii investigators. Pravastatin limitation of atherosclerosis in the coronary arteries. Am J Cardiol 76 9 (1995) 60C-63C
33. Jukema J.W., Bruschke A.V., van Boven A.J., Reiber J., Bal E., Zwinderman A., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 10 (1995) 2528-2540
34. Sawayama Y., Shimizu C., Maeda N., Tatsukawa M., Ninukawa N., Koyanagi S., et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka AtheroSclerosis Trial (FAST). J Am Coll Cardiol 39 4 (2002) 610-616
35. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G., Neil H., Livingstone J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
36. Holdaas H., Fellstrom B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al. on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 9374 (2003) 2024-2031
37. Sahni R., Maniet A.R., Voci G., and Banka V.S. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 121 6 Pt 1 (1991) 1600-1608
38. The pravastatin multinational study group for cardiac risk patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 To 7.8 Mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The pravastatin multinational study group for cardiac risk patients. Am J Cardiol 72 14 (1993) 1031-1037
39. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W., Cashin-Hemphill L., Hodis H., et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119 10 (1993) 969-976
40. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Frankin F., Grillo R., et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 74 7 (1994) 667-673
41. Furberg C.D., Adams H.P.J., Applegate W.B., Byington R., Espeland M., Hartwell T., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPS) research group. Circulation 90 4 (1994) 1679-1687
42. Waters D., Higginson L., Gladstone P., Kimball B., Le May M., Boccuzzi S., et al. the CCAIT Study Group. Effects of monotherapy with an hmg-coa reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 3 (1994) 959-968
43. Weintraub W.S., Boccuzzi S.J., Klein J.L., Kosinski A., King S., Ivanhoe R., et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin restenosis trial study group. N Engl J Med 331 20 (1994) 1331-1337
44. Anonymous. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344 8923 (1994) 633-638
45. Salonen R., Nyyssonen K., Porkkala E., Rummukainon J., Belder R., Park J.-S., et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 7 (1995) 1758-1764
46. Bertrand M.E., McFadden E.P., Fruchart J.C., Van Belle E., Commeau P., Grollier G., et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The predict trial investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty. J Am Coll Cardiol 30 4 (1997) 863-869
47. Bestehorn H.P., Rensing U.F., Roskamm H., Betz P., Benesch L., Schemeitat K., et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 18 2 (1997) 226-234
48. Wenke K., Meiser B., Thiery J., Nagel D., von Schiedt W., Steinbeck G., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96 5 (1997) 1398-1402
49. Herd J.A., Ballantyne C.M., Farmer J.A., Ferguson J., Jones P., Stewart West M., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 80 3 (1997) 278-286
50. ER3 M., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 12 (2003) 1481-1486
51. Nakagawa T., Kobayashi T., Awata N., Sato S., Reiber J., Nakajima H., et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the prevention of coronary sclerosis (PCS) study. Int J Cardiol 97 1 (2004) 107-114
52. Beishuizen E.D., van de Ree M.A., Jukema J.W., Tamsma J., van der Vijver J., Meinders A., et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 27 12 (2004) 2887-2892
53. Law M., Wald N., and Thompson S. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. Brit Med J 308 (1994) 367-372
54. Law M., Wald N., and Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit J Med 326 (2003) 1423-1429
55. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
56. Bucher H.C., Griffith L.E., and Guyatt G.H. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arteriosclerosis, Thrombosis & Vascular Biology 19 2 (1999) 187-195
57. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 4 (1997) 313-321
58. Ross S.D., Allen I.E., Connelly J.E., Korenblat B., Eugene Smith M., Bishop D., et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 159 15 (1999) 1793-1802
59. Anonymous. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The post coronary artery bypass graft trial investigators. N Engl J Med 336 3 (1997) 153-162
60. Anonymous. Results of the low-dose (20 mg) pravastatin gissi prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Gissi prevenzione investigators (gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico). Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 1 12 (2000) 810-820
61. Wilt T.J., Bloomfield H.E., MacDonald R., Nelson D., Rucks I., Ho M., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 13 (2004) 1427-1436
62. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the scandinavian simvastatin survival study (4s). Circulation 97 15 (1998) 1453-1460
63. Sacks F.M., Moye L.A., Davis B.R., Cole T., Rouleau J., Nash D., et al. Relationship between plasma ldl concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97 15 (1998) 1446-1452
64. Buyse M., Thirion P., Carlson R.W., Burzykowski T., Molenberghs G., and Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in cancer. Lancet 356 9227 (2000) 373-378
65. Shanafelt T.D., Loprinzi C., Marks R., Novotny P., and Sloan J. Are chemotherapy response rates related to treatment -induced survival prolongations in patients with advanced cancer?. J Clin Oncol 22 10 (2004) 1966-1974
66. Korn E.L., Albert P.S., and McShane L.M. Assess surrogates as trial endpoints using mixed models. Stat Medicine 24 (2005) 163-182
67. Molenberghs G., Buyse M., Geys H., Renard D., Burzykowski T., and Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials 23 (2002) 607-625
68. Burzykowski T., and Buyse M. Surrogate threshold effect. An alternative measure of meta-analytic surrogate endpoint validation. Pharmaceutical Statistics 5 (2006) 173-186
69. Lassere M: The biomarker-surrogacy evaluation schema: A review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional, hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res first published on October 9, 2007 as doi:10.1177/0962280207082719.
70. Xu J., and Zeger S. The evaluation of multiple surrogate endpoints. Biometrics 57 (2001) 81-87
71. Trewby P.N., Reddy A.V., Trewby C.S., Ashton V.J., Brennan G., and Inglis J. Are preventive drugs preventive enough? A study of patients' expectations of benefit from preventive drugs. Clin Med 2 (2002) 527-533
72. Kassaï B., Shah N.R., Leizorovaicza A., Cucherat M., Gueyffier F., and Boissel J.-P. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol 58 (2005) 1042-1051